Welcome to our dedicated page for Nkarta SEC filings (Ticker: NKTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nkarta, Inc. filings document the regulatory record of a clinical-stage biotechnology company advancing engineered NK cell therapies for autoimmune disease. Recent 8-K reports disclose quarterly and annual financial results, corporate highlights, and clinical-program references for NKX019 and the Ntrust studies.
The company’s proxy materials cover annual meeting governance, director elections, auditor ratification, executive compensation votes, and stockholder voting mechanics. Other filings describe capital-raising infrastructure, including a Form S-3 registration statement and an at-the-market sales agreement for common stock, as well as emerging growth company reporting status and related Exchange Act disclosures.
Nkarta reported a significant insider transaction involving Chief Medical Officer and Head of R&D, Shawn Marshall Rose. On June 23, 2025, Rose was granted stock options to purchase 500,000 shares of common stock at an exercise price of $1.75 per share.
The stock options have a structured vesting schedule:
- 25% of the options vest on July 23, 2026
- Remaining 75% vest in 36 equal monthly installments following June 23, 2026
- Options expire on June 22, 2035
This grant suggests a long-term retention strategy for a key executive, with the low exercise price potentially indicating recent stock price challenges or an incentive-focused compensation structure. The substantial size of the grant (500,000 shares) reflects the senior leadership position and importance of the R&D function to the company.
Form 3 Initial Statement of Beneficial Ownership filed for Nkarta (NKTX) on June 28, 2025, reporting the beneficial ownership status of Shawn Marshall Rose, who has been appointed as the company's Chief Medical Officer and Head of Research & Development.
Key details:
- Filing Date: June 28, 2025
- Event Date: June 23, 2025
- Location: South San Francisco, CA
- Filing Type: Individual filing
- Current Holdings: No securities beneficially owned
This Form 3 indicates that the executive currently holds no derivative or non-derivative securities in the company. The filing was signed by Bridgette Housley as Attorney-in-Fact on June 25, 2025, and includes a Power of Attorney as Exhibit 24.
Nkarta, Inc. (NKTX) – Form 4 Insider Transaction Overview
CEO and Director Paul J. Hastings disclosed the sale of 1,790 common shares on 06/18/2025 at a weighted-average price of $1.79. The transaction was automatically executed to satisfy tax-withholding obligations triggered by the vesting and settlement of Restricted Stock Units and therefore was not a discretionary sale. Following the sale, Hastings continues to beneficially own 320,069 shares, which includes 2,000 shares purchased under Nkarta’s 2020 Employee Stock Purchase Plan on 05/31/2025.
No derivative securities were acquired or disposed of, and no additional transactions were reported. Given the small size of the sale—roughly 0.56% of the executive’s total holdings—the filing appears routine and does not signal any change in corporate strategy, financial position, or insider sentiment.